We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
Cap. Flow
-$176M
Cap. Flow %
-4.93%
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$79.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$45.9M
3
PCVX icon
Vaxcyte
PCVX
+$45.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$38.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$158M
2
RLMD icon
Relmada Therapeutics
RLMD
+$88.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$43.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.4M
5
EW icon
Edwards Lifesciences
EW
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Financials 0.08%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
51
Verrica Pharmaceuticals
VRCA
$84.9M
$13.9M 0.39%
503,898
– –
AXGN icon
52
Axogen
AXGN
$2.68B
$13.9M 0.39%
1,388,126
+438,500
+46% +$4.87M
RVNC
53
DELISTED
Revance Therapeutics, Inc.
RVNC
$13.5M 0.38%
729,097
-79,574
-10% -$1.82M
CTKB icon
54
Cytek Biosciences
CTKB
$595M
$13.2M 0.37%
1,289,534
– –
AORT icon
55
Artivion
AORT
$1.29B
$13.2M 0.37%
1,085,860
-118,369
-10% -$1.42M
BBIO icon
56
BridgeBio Pharma
BBIO
$15.7B
$12.9M 0.36%
1,697,033
– –
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12.6M 0.35%
587,400
-446,769
-43% -$9.54M
NBIX icon
58
Neurocrine Biosciences
NBIX
$15.6B
$11.9M 0.34%
100,050
– –
LRMR icon
59
Larimar Therapeutics
LRMR
$432M
$11.8M 0.33%
2,860,000
– –
CMAX
60
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$11.4M 0.32%
104,307
-8,858
-8% -$1.32M
ISRG icon
61
Intuitive Surgical
ISRG
$131B
$10.6M 0.3%
+40,000
New +$9.75M
MORF
62
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.72M 0.27%
363,197
– –
DICE
63
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$9.15M 0.26%
293,362
-394,062
-57% -$12.9M
LABP
64
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$7.43M 0.21%
1,486,992
– –
SCPH
65
DELISTED
scPharmaceuticals
SCPH
$6.83M 0.19%
+952,380
New +$5.82M
HLVX
66
DELISTED
HilleVax
HLVX
$6.79M 0.19%
406,024
-358,883
-47% -$6.48M
OMIC
67
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$6.6M 0.19%
109,409
-8,467
-7% -$567K
ISO
68
DELISTED
IsoPlexis Corporation Common Stock
ISO
$6.35M 0.18%
4,095,498
– –
PEN icon
69
Penumbra
PEN
$12.8B
$5.65M 0.16%
+25,400
New +$4.97M
ACRS icon
70
Aclaris Therapeutics
ACRS
$963M
$5.37M 0.15%
341,239
– –
NTRA icon
71
Natera
NTRA
$48.5B
$5.22M 0.15%
130,000
+10,000
+8% +$412K
CBAY
72
DELISTED
Cymabay Therapeutics
CBAY
$4.45M 0.12%
+708,993
New +$2.69M
FLNA
73
PUT
Filana Therapeutics
FLNA
$45.8M
$4.43M 0.12%
+150,000
New +$5.39M
NVNO
74
enVVeno Medical
NVNO
$7.5M
$3.99M 0.11%
22,332
– –
NBTX
75
Nanobiotix
NBTX
$2.11B
$3.89M 0.11%
1,059,800
– –
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $176M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.

  • Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
  • Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
  • Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
  • Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
  • Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.